NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans remained in control of the Senate. The Dow Jones Industrial Average jumped 2.13 percent to close at 26,180.30, while the S&P 500 Index hiked 2.12 percent to close at 2,813.89. The Nasdaq Composite Index closed 2.64 percent higher to close at 7,570.75.
“As President Trump plans his 2020 reelection campaign, a gridlocked Congress is unlikely to deliver any notable wins to help expand his agenda. Therefore, Trump will likely focus on his broad executive powers to affect trade and national security,” said Sun Life Investment Management managing director, investment strategy, Dec Mullarkey.
RDI Initiates Coverage on:
Intercept Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Intercept Pharmaceuticals' stock jumped 4.65% Wednesday, to close the day at $114.46. The stock recorded a trading volume of 571,343 shares, which was above its three months average volume of 466,638 shares. In the last year, Intercept Pharmaceuticals' shares have traded in a range of 51.05 - 133.74. The share price has gained 124.21% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $107.18 is above its 200-day moving average of $94.09. Shares of Intercept Pharmaceuticals have gained roughly 2.58 percent in the past month and are up 95.93 percent year-to-date.
Access RDI's Intercept Pharmaceuticals, Inc. Research Report at:
On Wednesday, shares of Seattle Genetics recorded a trading volume of 782,409 shares, which was below the three months average volume of 923,883 shares. The stock ended the day 4.98% higher at $60.95. The share price has fallen 27.76% from its 52
Access RDI's Seattle Genetics, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.